Review Article

Clinical Features in Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency: A Systematic Review

Susanna Rizzi (1,1), Carlotta Spagnoli (1,1), Daniele Frattini (1,1), Francesco Pisani (2,2), and Carlo Fusco (1,1)

1 Child Neurology and Psychiatry Unit, Department of Pediatrics, Presidio Ospedaliero Santa Maria Nuova, AUSL-IRCCS di Reggio Emilia, Reggio Emilia 42123, Italy
2 Child Neurology Unit, University of Parma, 43100 Parma, Italy

Correspondence should be addressed to Carlotta Spagnoli; carlotta.spagnoli@ausl.re.it

Received 25 May 2022; Revised 1 September 2022; Accepted 22 September 2022; Published 11 October 2022

Aromatic L-amino acid decarboxylase (AADC) deficiency is a rare congenital autosomal recessive metabolic disorder caused by pathogenic homozygous or compound heterozygous variants in the dopa decarboxylase (DDC) gene. Adeno-associated viral vector-mediated gene transfer of the human AADC gene into the putamina has become available. This systematic review on PubMed, Scopus databases, and other sources is aimed at describing the AADC whole phenotypic spectrum in order to facilitate its early diagnosis. Literature reviews, original articles, retrospective and comparative studies, large case series, case reports, and short communications were considered. A database was set up using Microsoft Excel to collect clinical, molecular, biochemical, and therapeutic data. By analysing 261 patients from 41 papers with molecular and/or biochemical diagnosis of AADC deficiency for which individuality could be determined with certainty, we found symptom onset to occur in the first 6 months of life in 93% of cases. Hypotonia and developmental delay are cardinal signs, reported as present in 73.9% and 72% of cases, respectively. Oculogyric crises were seen in 67% of patients while hypokinesia in 42% and ptosis in 26%. Dysautonomic features have been revealed in 53% and gastrointestinal symptoms in 19% of cases. With 37% and 30% of patients reported being affected by sleep and behavioural disorders, it seems to be commoner than previously acknowledged.

Although reporting bias cannot be excluded, there is still a need for comprehensive clinical descriptions of symptoms at onset and during follow-up. In fact, our review suggests that most of the neurological and extraneurological symptoms and signs reported, although quite frequent in this condition, are not pathognomonic, and therefore, ADCC deficiency can remain an underdiscovered disorder.

1. Introduction

Aromatic L-amino acid decarboxylase (AADC) deficiency (OMIM #608643) is a rare congenital autosomal recessive metabolic disorder due to pathogenic homozygous or compound heterozygous variants in the dopa decarboxylase (DDC) gene. The AADC enzyme is required for the final decarboxylation step, resulting in the synthesis of monoamine neurotransmitters. AADC enzymatic deficiency leads to a severe combined deficiency of serotonin and dopamine and consequently of norepinephrine and epinephrine.

The global incidence of AADC deficiency is unknown, but it is more prevalent in Asian populations (especially Taiwanese and Japanese), probably due to a founder effect [1]. The neonatal prevalence of AADC deficiency has been estimated to be approximately 1/42000 [2], and a newborn screening program testing 3-O-methyldopa (3-OMD) on dried blood spots performed in Taiwan revealed a prevalence of about 1/32000 [3]. In the high-risk population (i.e., patients with suspicion of biogenic amine neurotransmitter disorder), the prevalence is approximately 0.112% or roughly 1:900 [2]. In the Asian at-risk population, the prevalence is 50% higher than in the non-Asian population [4].

The phenotypic spectrum is broad and can range from very severe to relatively mild phenotypes. Clinical manifestations of AADC include neurological and nonneurological
symptoms. Common and less common signs and symptoms are reported in Table 1 [5]. The typical presentation is characterized by early-onset hypotonia, movement disorders (oculogyric crisis, dystonia, and hypokinesia), developmental delay, and dysautonomia (nasal congestion, abnormal sweating, and excessive drooling and temperature instability). Pseudomyasthenic features, such as ptosis and fatigue with evening worsening, are often reported. Sleep disturbances, behavioural disorders (irritability, dysphoria, and autism-like symptoms), and gastrointestinal symptoms (gastroesophageal reflux, diarrhoea, and constipation) are common. Hypoglycemic episodes in infancy may be associated, while epilepsy is a rare finding. In recent years, mild and atypical phenotypes have been reported, increasing diagnostic challenge. The great majority of described patients (about 80%) are classified as having a severe phenotype (no or very limited developmental milestones, fully dependent) [6]. It is possible that patients with mild or moderate phenotypes are easily undiagnosed, a frequent issue in rare diseases.

The first laboratory diagnostic method is cerebrospinal fluid (CSF) neurotransmitter analysis. The characteristic pattern of CSF abnormalities in patients with AADC deficiency is characterized by biochemical product decrease (low homovanillic acid and 5-hydroxyindoleacetic acid levels) and biochemical precursor increase (elevated L-dopa, 5-hydroxytryptophan, and 3-ortho-methyldopa levels). However, CSF analysis requires a lumbar puncture, which, being invasive, is not primarily considered for patients with unspecific presentations. A less invasive, faster, and cheaper test consists in measuring plasma 3-OMD levels in dried blood spots, which are usually high in patients with AADC deficiency. Of note, urinary organic acids might also prove helpful in revealing a suggestive pattern of AADC deficiency, with moderate elevation of vanillactic and vanilpyruvic acids and slight N-acetylvanilalanine elevation. Finally, diagnosis can be genetically confirmed by detecting pathogenic homozygous or compound heterozygous variants in the DDC gene [6].

Concerning therapy, first-line treatment agents include selective dopamine agonists, MAO inhibitors, and vitamin B6. Additional symptomatic treatment is based on anticholinergic agents for autonomic symptoms, melatonin for sleep disorders, and benzodiazepines for movement disorders. Generally, patients require polytherapy, but, finally, gene therapy recently becomes available and leads to improved motor and cognitive performances, and it is generally well tolerated [7]. In several studies, early diagnosis has been suggested to improve treatment efficacy, and individuals with mild and moderate phenotypes seem to show better response [5, 8]. Therefore, for gene therapy to be an option and to modify the natural history of this disorder, an early diagnosis is recommended, although it is rarely achieved.

The primary objective of our review is to better define AADC deficiency-related clinical phenotype, by systematically reviewing previously reported patients in order to describe both severely and mildly affected cases. We collected a large case series with the aim of highlighting early diagnostic keys useful for paediatric neurologists.

### Table 1: Signs and symptoms reported in patients with AADC deficiency.

| Common | Less common |
|--------|-------------|
| (i) Hypotonia | (i) Infantile episodes of hypoglycemia |
| (ii) Developmental delay | (ii) Behavioural disorders (irritability, dysphoria, and autism-like symptoms) |
| (iii) Movement disorders (oculogyric crisis, dystonia, and hypokinesia) | (iii) Sleep disorders (sleepiness or insomnia) |
| (iv) Dysautonomia (nasal congestion, abnormal sweating, excessive drooling, hypotension, bradycardia, and temperature instability) | (iv) Gastrointestinal symptoms (gastroesophageal reflux, diarrhoea, and constipation) |
| (v) Pseudomyasthenic features (ptosis and fatigability) | (v) Epilepsy |

### 2. Materials and Methods

A systematic literature review on AADC deficiency was performed between July and December 2021 on PubMed and Scopus databases, using “Aromatic L-Amino Acid Decarboxylase Deficiency” and “AADC deficiency” as search terms. The language filter “English” was used. Literature reviews, original articles, retrospective and comparative studies, large case series, case reports, and short communications were considered. People of any age or gender with a molecular and/or biochemical diagnosis of AADC deficiency for which individuality could be determined with certainty were included. We excluded case reports in which it was not possible to establish whether the patient had already been described or not. Reviews for which it was not possible to trace previous descriptions of individual patients were also excluded. A database was set up using Microsoft Excel to collect clinical, molecular, biochemical, and therapeutic data (see database in Supplementary Materials (available here)). Authorship on the description of patients with AADC deficiency was attributed to the author who primarily or more accurately described them. However, if a second author subsequently added useful information, especially on the clinical course, both authors’ names and relative publications were considered. General information about sex, ethnicity, and biometric parameters at birth and during growth, age at symptom onset, and age at diagnosis were noted. Specific data concerning DDC gene variants, AADC enzymatic activity, plasma 3-OMD levels, and CSF neurotransmitter profile were included, if available. Regarding the symptoms, we divided them into neurological and non-neurological and catalogued them as present or absent. Finally, therapeutic attempts and their reported efficacy were included. We assessed the efficacy of the therapy only qualitatively, without any standardized scales, and categorized the response as absent, poor, mild, or favourable. In line with the review protocol, we synthesized available evidence.
narratively and graphically using percentages. One reviewer performed the initial data extraction for all included articles and database entry, and a second reviewer independently checked all processes. A third reviewer supervised data extraction and resolved conflicts.

3. Results and Discussion

3.1. Results. Our search showed 305 records (115 from PubMed and 190 from Scopus databases), but patients’ description was found in 32 records. We identified an additional 13 records by checking additional sources (i.e., reference lists of reviewed articles)—therefore, a total of 45 records were identified. We excluded 4 records, either because articles were written in Chinese \((n = 2)\) [9, 10] or because it was not possible to trace the individuality of described patients \((n = 2)\) [11, 12]. As a result, 41 records were included in this review [1–3, 7, 8, 13–48]. Please refer to Table 2 and the flow diagram in Supplementary Materials.

3.1.1. Clinical Features. Data from 261 patients were analysed (117 females, 112 males, and 32 NA). The age of onset of signs and symptoms was clearly documented in 194 patients: it was at birth in 9 patients, within the 3rd month of life in 40 patients, within the 6th month of life in 181 patients, between 6 months and 1 year in 11 patients, and beyond 1 year of life in 2 patients (see Figure 1).

Signs and symptoms of AADC deficiency were distributed as follows (see Figure 2): hypotonia (present in 193 patients, absent/not mentioned in 68), developmental delay (present in 188, absent in 2, and not mentioned in 71), oculogyric crises (present in 177, absent/not mentioned in 84), autonomic symptoms (present in 138, absent/not mentioned in 123), hypokinesia (present in 110, absent/not mentioned in 151), sleep disorders (present in 96, absent/not mentioned in 165), dystonia (present in 93, absent/not mentioned in 168), behavioural disorders (present in 79, absent/not mentioned in 18), ptosis (present in 68, absent/not mentioned in 193), gastrointestinal issues (present in 50, absent/not mentioned in 211), hypoglycemia (present in 26, absent/not mentioned in 235), and epilepsy (present in 12, absent/not mentioned in 249).

3.1.2. Diagnosis. Genetic diagnosis was available for 201 patients: 119 were compound heterozygous and 82 homozygous. Regarding homozygous variants, ethnic origin was specified in 51 patients: 34 Asians, 12 Caucasians (7 German and 5 Italian), 3 Arabs, 1 Indian, and 1 Turkish.

CSF analysis was available in 92 patients, and all showed the typical pattern. Enzymatic activity was reduced and plasma 3-OMD increased in all tested patients: 79 and 29, respectively. Hyperprolactinemia was reported in 12 patients. Neuroimaging data are available in 91 patients: 55 show normal results and 36 have nonspecific findings, such as atrophic changes or white matter abnormalities. Of 75 available EEG recordings, 52 were normal and 23 showed nonspecific changes, such as abnormal background. Interictal epileptiform discharges, such as spikes or sharp-waves, were reported in four patients.

3.1.3. Therapy and Outcome. As long as therapy is concerned, an improvement with vitamin B6 was reported in 49/128 patients, with DOPA agonists in 82/149 patients and with MAO inhibitors in 35/62 patients.

All patients undergoing gene therapy (10/10) improved cognitive and motor performance.

3.1.4. Life Expectancy. Thirteen of the patients described died (13/261): 5 due to pneumonia, 2 due to complications during OGC, 1 to myocardial infarction, and 1 due to sepsis, while the cause is not reported in the remaining 4. Six patients died within 3 years, 2 within 10 years, 1 between ten and twenty years, and 2 over 20 years of age. For the remaining 2 patients, the age is not specified.

3.2. Discussion. More than 260 patients have been described in case reports, case series, and reviews since the initial description of the index family in 1990 [13].

3.2.1. Clinical Features. The age of onset of signs and symptoms, when documented, was confirmed to be within the first 12 months of life in 99% of patients, often within the first 6 months (93%). Only 2 patients (1% of reported cases) had their symptom onset after 1 year of life. The first, at the age of 3, had recurrent episodes of severe long-fasting hypoglycemia and diarrhoea [30] and the second, diagnosed by newborn’s screening, at the age of 2 showed “slightly awkward” walking and object manipulation [13].

Hypotonia and developmental delay are cardinal signs: hypotonia is reported as absent only in 4 patients [30, 36] and normal development is described only in two children [3, 30]. In detail, the patient described by Arnoux et al. [30] followed mainstream education in primary school and had speech therapy. The patient described by Chien et al. [3] received a full clinical evaluation only at the age of 6 months, while at age 2, a video recording was used, reducing diagnostic accuracy. More than half (about 68%) of reviewed patients had oculogyric crises. Movement disorders of the hypokinetic or dystonic type were present in 42% and 36% of patients, respectively. Dysautonomia was present in about half (53%) of the cases, with higher expression in early childhood. 37% of patients suffered from sleep disorders (insomnia or excessive sleepiness), while 30% had behavioural symptoms (irritability, emotional liability). About one-quarter (26%) of subjects have bilateral ptosis, often associated with fatigability and diurnal variation.

| Type of studies          | No. of records | References |
|-------------------------|----------------|------------|
| Case report             | 18             | [8, 13–15, 18, 22, 25, 27, 29, 30, 32–37, 39, 41] |
| Case series             | 10             | [1, 3, 19–21, 26, 38, 40, 42, 46] |
| Original article        | 8              | [7, 23, 28, 31, 43, 45, 47, 48] |
| Short communication     | 3              | [16, 17, 44] |
| Retrospective study     | 1              | [2]         |
| Comparative study       | 1              | [24]        |
features are mild delay in developmental milestones, walking

tures are also often associated [39]. Atypical presentation
symptoms, whose expression is maximal. Less common fea-
patients typically present with all the cardinal signs and
failure to reach any developmental milestones, full depen-
dence on caregivers, and, sometimes, early exitus [43]. These
patients typically present with all the cardinal signs and
symptoms, whose expression is maximal. Less common fea-
tures are also often associated [39]. Atypical presentation
features are mild delay in developmental milestones, walking
difficulties without assistance, and mild intellectual disability
or borderline cognitive performances [8, 36, 48]. Atypical
cases in whom only the least common features are present
are extremely rare. Arnoux et al. [30] described a 5-year-
old girl with normal development and apparently no cogni-
tive difficulties, who exclusively experienced recurrent epi-
isodes of severe long-fasting hypoglycemia and recurrent
aqueous diarrhoea [30]. Between the typical and the highly
atypical cases, there is a continuum of symptoms and signs,
which are difficult to recognize and to attribute specifically
to AADC deficiency. On the other hand, early diagnosis is
required to improve care and outcome. Importantly, a high
index of suspicion is required, as the initial manifestations
may be unspecific, such as hypotonia, developmental delay,
or gastrointestinal symptoms. Consequently, diagnosis is
often delayed [6].

3.2.2. Diagnosis. In most of the described patients, patho-
genic homozygous or compound heterozygous variants in
DCC gene were demonstrated, leading to genetic confirma-
tion. In fact, genetic diagnosis was available in 77% of
reported patients: in 60% of cases, a compound heterozygos-
ity was found, while the remaining 40% of cases were caused
by homozygous variants in the DDC gene. Homozygous var-
iants are clearly prevalent in the Asian population (66%
Asian, 24% Caucasians, and 10% other), validating the
hypothesis of a founder effect [1].

An easy-to-use and minimally invasive screening tool is
available in suspected cases: 3-OMD measurement on
blood-dried spots [50, 51]. Considering the diagnostic chal-
enges discussed above, this test can be proposed as a way to
investigate as many patients as possible, even with nontypi-
cal phenotypes. In this review, elevated 3-OMD has been
investigated in all AADC deficiency patients in whom the test
was performed. However, it was used only in 11% of the
studied population, while in the future, we advocate its
implementation as a screening method. It must be noted
that 3-OMD is also increased in PNPO deficiency [52],
which nevertheless has a different clinical presentation
[53]. However, a different method, ascertaining levels of
both 3-OMD and 5-hydroxytryptophan on dried blood
spots, has also been recently proposed [54].

Plasma AADC activity was severely decreased in all
tested AADC patients, and it may also be moderately
reduced in heterozygous carriers [6]. Hyperprolactinemia
was reported in only 4.5% of patients. When available,
patients always showed the typical AADC pattern in CSF.

Brain imaging and EEG, when available, revealed normal
findings or nonspecific abnormalities, confirming that they
are not helpful in diagnosing AADC deficiency [6].

3.2.3. Therapy and Outcome. About the therapeutic
approach, several drugs are available for symptomatic treat-
ment, including vitamin B6 (a coenzyme of AADC), dopa-
mine agonists, and monoamine oxidase (MAO) inhibitors.
Just over half of the patients benefited from DOPA agonists
and MAO inhibitor administration. An improvement in
vitamin B6 was reported only in 38% of patients. This liter-
ature review thus confirms previous knowledge that drug

Gastrointestinal symptoms were reported in 19% of patients.
Only 10% suffered from hypoglycemic episodes. Epilepsy
occurred in 4.5% of AADC deficiency patients; 2 of them
had symptomatic seizures secondary to hypoglycemia and
hydroelectrolytic imbalance during diarrhoea.

From our review, sleep and behavioural issues, consid-
ered less common by previous literature, emerge as more
frequent than ptosis or dystonia [5]. However, it is likely
that some features, considered less relevant and/or less dis-
tinctive, were not reported in the first descriptions, and
therefore, their frequency could be underreported: conse-
quent, these are probably still underdiagnosed. It is
therefore necessary to continue to carefully report on
patients with AADC deficiency to understand its characteris-
tics and the real prevalence of signs and symptoms, in order
to describe the complete phenotypic spectrum. The high
prevalence of nonspecific neurological and nonneurological
signs and symptoms together with the potential underesti-
mation or misinterpretation of the most typical neurological
presentations (such as oculogyric crises or ptosis) can result
in significant underdiagnosis or diagnostic delay [49].

The AADCD phenotypic spectrum ranges from rela-
tively mild to extremely severe, and clinical relevance of each
sign or symptom may differ among patients. Typical cases
show a severe phenotype characterized by neonatal onset,
failure to reach any developmental milestones, full depend-
ence on caregivers, and, sometimes, early exitus [43]. These
patients typically present with all the cardinal signs and
symptoms, whose expression is maximal. Less common fea-
tures are also often associated [39]. Atypical presentation
features are mild delay in developmental milestones, walking

![Figure 1: Age at onset in reviewed cases with AADC deficiency.](image)
treatment is not satisfactory, that response to medications is better in mild-to-moderate compared to severe cases, and that dopamine agonists and MAO inhibitors show better results than vitamin B6 [8, 18, 55, 56]. Adeno-associated viral vector-mediated (AAV2) gene transfer of the human AADC gene into the putamina was performed for the first time in 2012 [57]. All patients undergoing gene therapy, 4% of this review population, improved cognitive and motor performances [7, 55]. Motor improvements were also reported in the 10 patients described by Chien and colleagues; however, they were not included in this database due to their nontraceability [12]. The scientific literature supports the efficacy and safety of AAV2 gene therapy via intraputaminal injection for AADC patients. The genetic background is a determining factor in response to gene therapy: patients with greater residual genetic activity experience greater benefit. In fact, patients with moderate phenotypes show better improvement than severely affected patients [7]. From these observations, the importance of early diagnosis of mild-to-moderate phenotypes emerges as the best way to significantly impact the natural history of the disease.

3.2.4. Life Expectancy. Only 5% of the patients described are reported to have died, of whom 39% were due to pneumonia, 15% were due to complications during OGC, 8% were due to myocardial infarction, and 8% were due to sepsis, and for the remaining 30%, the cause is not reported. 46% of patients died within 3 years, 15.3% within the age of 10 years, 15.3% over 20 years of age, and 8% during the second decade. For the remaining 15.3%, age of death is not specified. It must be considered that, in many cases, patients were described shortly after diagnosis, and therefore, data on mortality were not reported, representing a bias in data collection. Of note, with the availability of gene therapy, mortality data are expected to change and should be the object of future studies.

4. Conclusions

In this systematic review, we confirmed the core clinical features of a rare autosomal recessive disorder of neurotransmitters, AADC deficiency, highlighting the commonest neurologic and nonneurologic signs and symptoms, the whole phenotypic spectrum from milder to severe forms, and the best currently available diagnostic and therapeutic approaches. Our review will provide paediatric neurologists with an updated description of the most relevant literature data to increase awareness of this rare disorder, with the aim not to miss diagnoses and to improve long-term outcomes by prompt treatment initiation.

Data Availability

The data supporting this systematic review are from previously reported studies and datasets, which have been cited. The processed data are available in the supplementary file.

Conflicts of Interest

The authors declare that they have no conflict of interest to disclose.

Acknowledgments

The study was funded by the unconditional support for medical writing received by Medical Affairs PTC Italy.

Supplementary Materials

Supplementary materials contain a database with the whole list of reviewed studies, with the clinical, laboratory, and genetic data extracted from each paper and flow diagram summarizing the identification process of the included studies in this systematic review. (Supplementary Materials)
transmitter disorder mimicking as dyskinetic cerebral palsy," *J Pediatr Genet*, vol. 10, no. 2, pp. 85–91, 2021.

[46] F. Kubaski, Z. M. Herbst, D. A. A. Pereira et al., "Evaluation of 3-O-methyldopa as a biomarker for aromatic L-amino acid decarboxylase deficiency in 7 Brazilian cases," *Molecular genetics and metabolism reports*, vol. 27, article 100744, 2021.

[47] C. Longo, R. Montoli, G. Bisello et al., "Compound heterozygosis in AADC deficiency: a complex phenotype dissected through comparison among heterodimeric and homodimeric AADC proteins," *Molecular Genetics and Metabolism*, vol. 134, no. 1-2, pp. 147–155, 2021.

[48] Y. Hasegawa, E. Nishi, Y. Mishima et al., "Novel variants in aromatic L-amino acid decarboxylase deficiency: case report of sisters with mild phenotype," *Brain Dev*, vol. 43, no. 10, pp. 1023–1028, 2021.

[49] C. Fusco, V. Leuzzi, P. Striano, R. Battini, A. Burlina, and C. Spagnoli, "Aromatic L-amino acid decarboxylase (AADC) deficiency: results from an Italian modified Delphi consensus," *Italian Journal of Pediatrics*, vol. 47, no. 13, 2021.

[50] P. W. Chen, N. C. Lee, Y. H. Chien, J. Y. Wu, P. C. Wang, and W. L. Hwu, "Diagnosis of aromatic L-amino acid decarboxylase deficiency by measuring 3-O- _O_ -methyl-dopa concentrations in dried blood spots," *Clinica Chimica Acta*, vol. 431, pp. 19–22, 2014.

[51] A. Burlina, A. Giuliani, G. Polo et al., "Detection of 3-O-methyldopa in dried blood spots for neonatal diagnosis of aromatic L-amino-acid decarboxylase deficiency: the northeastern Italian experience," *Molecular Genetics and Metabolism*, vol. 133, no. 1, pp. 56–62, 2021.

[52] K. Hyland, "Clinical utility of monoamine neurotransmitter metabolite analysis in cerebrospinal fluid," *Clinical Chemistry*, vol. 54, no. 4, pp. 633–641, 2008.

[53] T. L. Ware, J. Earl, G. S. Salomons et al., "Typical and atypical phenotypes of PNPO deficiency with elevated CSF and plasma pyridoxamine on treatment," *Developmental Medicine and Child Neurology*, vol. 56, no. 5, pp. 498–502, 2014.

[54] E. Di Carlo, S. Santagata, L. Sauro et al., "Simultaneous determination of 5-hydroxytryptophan and 3-O-methyldopa in dried blood spot by UPLC-MS/MS: a useful tool for the diagnosis of L-amino acid decarboxylase deficiency," *Journal of Chromatography B Analytical Technol Biomed Life Sci*, vol. 1185, article 122999, 2021.

[55] M. Bergkvist, C. Stephens, T. Schilling et al., "Aromatic L-amino acid decarboxylase deficiency – a systematic review," *Posters*, vol. 493, p. iCIEM, 2022.

[56] M. Mastrangelo, C. Caputi, S. Galosi, M. T. Giannini, and V. Leuzzi, "Transdermal rotigotine in the treatment of aromatic L-amino acid decarboxylase deficiency," *Movement Disorders*, vol. 28, no. 4, pp. 556–557, 2013.

[57] W. L. Hwu, S. I. Muramatsu, S. H. Tseng et al., "Gene therapy for Aromaticl-Amino acid decarboxylase deficiency," *Science Translational Medicine*, vol. 4, no. 134, article 134Ra61, 2012.